Document is current
Any future updates will be listed below
-
Authors
Matson, Daniel R. http://orcid.org/0000-0003-1430-3128
Denu, Ryan A.
Zasadil, Lauren M.
Burkard, Mark E.
Weaver, Beth A.
Flynn, Christopher
Stukenberg, P. Todd
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (T32 HL07899)
The Women’s 4 Miler Breast Care Fund at the University of Virginia Cancer Center
Department of Pathology and Laboratory Medicine, University of Wisconsin - Madison (P30 CA014520)
NIH Office of the Director (S10OD023526)
Cancer Center Support Grant (P30 CA014520)
- License Information
-
More Information
Article History
Received: 29 September 2020
Accepted: 8 February 2021
First Online: 23 February 2021
Ethics approval and consent to participate
: Tumors used to construct the TMAs utilized in this study were obtained from patients being treated at University of Wisconsin Carbone Cancer Center under protocol OS10111. Creation of the de-identified TMA and clinical data set were approved by the University of Wisconsin Health Sciences Institutional Review Board (IRB approval 2010–0405). The IRB waived patient consent.All biospecimen samples (tissue microarrays) were utilized under the University of Wisconsin – Madison’s Carbone Cancer Center’s Translational Science Biocore BioBank’s “Honest Broker” IRB protocol (Protocol 2016–0934), which allows distribution of biospecimens with coded patient data. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies involving animals performed by any of the authors.
: Not applicable.
: M.E.B. declares the following: Medical advisory board of Strata Oncology; Research funding from Abbvie, Genentech, Puma, Arcus, Apollomics, and Loxo Oncology. The other authors declare no competing interests.
